Found 4 articles
DEINOVE announces that its Board of Directors has approved the consolidated financial statements for the year 2021.
Pfizer's Clostridioides difficile infection vaccine failed to hit the mark, BMS announced priority review for Opdivo in resectable Non-Small Cell Lung Cancer, and Saol enlists help from GeneDx.
1/10/2022The biopharma industry has started 2022 with plenty of clinical trial news. Here’s a look.
DEINOVE announces a favorable opinion from the DSMB for the continuation of the Phase II clinical trial of DNV3837 in Clostridioides difficile infections
DEINOVE (Euronext Growth Paris, ALDEI), a French biotech company, pioneer in the exploration and exploitation of bacterial biodiversity to address the urgent, global challenge of antibiotic resistance, announced today that the independent Data Safety Monitoring Board (DSMB) has completed its review of the safety data from the first part of the Phase II clinical trial of DNV3837 in the treatment of Clostridioides difficile infection (CDI).